E-Z-EM Comments on Patent Infringement Lawsuit Related to Empower Injector

  
    
  
  
    
      E-Z-EM, Inc., (NASDAQ:EZEM) today announced that Tyco Healthcare 
      Group LP filed a lawsuit against the Company in the federal district 
      court in Texas alleging patent infringement related to E-Z-EM’s 
      Empower®CT and Empower®CTA 
      injector systems. This lawsuit alleges infringement of a single U.S. 
      patent concerning medical fluid injectors.
    
    
      Commenting on the lawsuit, Anthony A. Lombardo, President and CEO said, “The 
      Company respects the intellectual property rights of others and intends 
      to vigorously defend against this action.”
    
    
      About E-Z-EM, Inc.
    
    
      E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal 
      radiology. The Company is the developer of VoLumen®—a 
      patent-pending, next generation low density barium sulfate suspension 
      for use as an oral contrast in Multidetector CT (MDCT) and Positron 
      Emission Tomography (PET/CT) studies. The Company also offers Empower®?the 
      only family of CT injectors on the market with patented EDA™ 
      technology that can help detect contrast extravasation?and 
      offers a complete product set for the virtual colonoscopy practitioner. 
      This product line consists of virtual colonoscopy hardware, software, 
      nutritional prep kits and bowel cleaners, tagging agents and a carbon 
      dioxide colon insufflation system. The Company is also the exclusive 
      world-wide manufacturer and marketer of RSDL for first-responder 
      organizations and military services. RSDL is a patented, broad-spectrum 
      liquid chemical warfare (CW) agent decontaminant, that neutralizes or 
      removes chemical agents from skin on contact, leaving a non-toxic 
      residue that can be rinsed off with water.
    
    
      The statements made in this document contain certain forward-looking 
      statements. Words such as “expects,” 
      “intends,” “anticipates,” 
      “plans,” “believes,” 
      “seeks,” “estimates” 
      or variations of such words and similar expressions, are intended to 
      identify such forward-looking statements. The forward-looking statements 
      contained in this release may involve numerous risks and uncertainties, 
      known and unknown, beyond the Company’s 
      control. Such risks and uncertainties include: the ability of the 
      Company to develop its products; the outcome and impact of any lawsuit 
      involving Tyco Healthcare Group LP; future actions by the FDA or other 
      regulatory agencies, overall economic conditions, general market 
      conditions, price increases of raw materials and components, foreign 
      currency exchange rate fluctuations as well as the risk factors listed 
      from time to time in the SEC filings of E-Z-EM, Inc., including but not 
      limited to its Annual Report on Form 10-K for the fiscal year ended June 
      3, 2006 and its Form 10-Q for the quarter ended March 3, 2007. 
      Consequently, actual future results may differ materially from the 
      anticipated results expressed in the forward-looking statements, and 
      investors are cautioned not to place undue reliance on the 
      forward-looking statements included in this release.